Effects of recombinant human erythropoietin in normal humans

Journal of Physiology

Volumn 589, Issue 6, 2011, Pages 1265-1271

  Lundby, Carsten ^a   Olsen, Niels Vidiendal ^b,c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ERYTHROPOIETIN; FERROPORTIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; RECOMBINANT ERYTHROPOIETIN; RENIN; SOMATOMEDIN; VASCULOTROPIN;

ANGIOGENESIS; ARTERIAL PRESSURE; BLOOD VISCOSITY; COGNITION; DRUG SAFETY; ERYTHROCYTE VOLUME; EXERCISE; FEEDBACK SYSTEM; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HEMATOCRIT; HEMODYNAMIC PARAMETERS; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; LIPID METABOLISM; MUSCLE CELL; NORMAL HUMAN; OXYGEN CONSUMPTION; PLASMA VOLUME; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; VOLUNTEER;

ANIMALS; CELL SIZE; ERYTHROCYTES; ERYTHROPOIESIS; ERYTHROPOIETIN; EXERCISE TOLERANCE; HEMOGLOBINS; HUMANS; MUSCLE, SKELETAL; PLASMA VOLUME;

EID: 79952589438     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.195917     Document Type: Review

References (52)

1. Allegra V, Martimbianco L & Vasile A (1997). Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant 12, 924-932.
2. Allegra V, Mengozzi G, Martimbianco L & Vasile A (1996). Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 16, 304-308.
3. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M-T, Marion B & Bressolle F (1999). Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 31, 639-645.
4. Berglund B & Ekblom B (1991). Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med 229, 125-130.
5. Birkeland KI, Stray-Gundersen JIM, Hemmersbach P, Hallen J, Haug E & Bahr R (2000). Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 32, 1238-1243.
6. Bode-Böger SM, Böger RH, Kuhn M, Radermacher J & Frölich JC (1996). Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50, 1255-1261.
7. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T & Kirilov G (1993). Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant 8, 93-
8. Briggs J, Skøtt O & Schnermann J (1990). Cellular mechanisms within the juxtaglomerular apparatus. Am J Hypertens 3, 76-80.
9. Chang C, Chen Y, Modi K, Awar O, Alfrey C & Rice L (2009). Changes of red blood cell surface markers in a blood doping model of neocytolysis. J Investig Med 57, 650-654.
10. Clavell AL, Stingo AJ, Margulies KB, Brandt RR & Burnett JC Jr (1995). Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol Renal Physiol 268, F455-F460.
11. Connes P, Perrey S, Varray A, Préfaut C & Caillaud C (2003). Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 447, 231-238.
12. Dicato M & Plawny L (2010). Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol 22, 307-311.
13. Donnelly S (2003). Why is erythropoietin made in the kidney? The kidney functions as a 'critmeter' to regulate the hematocrit. Adv Exp Med Biol 543, 73-87.
14. Dunn A, Lo V & Donnelly S (2007). The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit. Am J Med Sci 334, 65-71.
15. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J, Falkai P, Rüther E, Aldenhoff JB & Krampe H (2007). Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12, 206-220.
16. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jahnig P, Herrmann M, Knauth M, Bahr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C & for the EPO Stroke Trial Group (2009). Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40, e647-656.
17. Freudenthaler SM, Lucht I, Schenk T, Brink M & Gleiter CH (2000). Dose-dependent effect of angiotensin II on human erythropoietin production. Pflugers Arch 439, 838-844.
18. Gossmann J, Burkhardt R, Harder S, Lenz T, Sedlmeyer A, Klinkhardt U, Geiger H & Scheuermann E-H (2001). Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 60, 83-86.
19. Heidenreich S, Rahn K & Zidek W (1991). Direct effects of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39, 259-265.
20. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK & Gehl J (2009). Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS ONE 4, e5894.
21. Holstein-Rathlou NH (1991). A closed-loop analysis of the tubuloglomerular feedback mechanism. Am J Physiol Renal Physiol 261, F880-F889.
22. Jelkmann W (2007). Erythropoietin after a century of research: younger than ever. Eur J Haematol 78, 183-205.
23. Juel C, Thomsen J, Rentsch R & Lundby C (2007). Effects of prolonged recombinant human erythropoietin administration on muscle membrane transport systems and metabolic marker enzymes. Eur J Appl Physiol 102, 41-44.
24. Kokot F, Wiecek A, Mesjasz J, Adamczak M & Spiechowicz U (1998). Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 13, 1200-1205.
25. Krapf R & Hulter HN (2009). Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 4, 470-480.
26. Lasne F, Martin L, Crepin N & de Ceaurriz J (2002). Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311, 119-126.
27. Lundby C, Achman-Andersen NJ, Thomsen JJ, Norgaard AM & Robach P (2008a). Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing. J Appl Physiol 105, 417-419.
28. Lundby C & Damsgaard R (2006). Exercise performance in hypoxia after novel erythropoiesis stimulating protein treatment. Scand J Med Sci Sports 16, 35-40.
29. Lundby C, Hellsten Y, Jensen MBF, Munch AS & Pilegaard H (2008b). Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol 104, 1154-1160.
30. Lundby C, Robach P, Boushel R, Thomsen JJ, Rasmussen P, Koskolou M & Calbet JAL (2008c). Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? J Appl Physiol 105, 581-587.
31. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JAL & Robach P (2007). Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 578, 309-314.
32. Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM & Harmer CJ (2008). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res 184, 313-321.
33. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ & Harmer CJ (2009). Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology (Berl) 207, 133-142.
34. Ninot G, Connes P & Caillaud C (2006). Effects of recombinant human erythropoietin injections on physical self in endurance athletes. J Sports Sci 24, 383-391.
35. Olsen NV, Aachmann-Andersen NJ, Oturai P, Andersen TM, Rasmussen AB, Hulston C, Holstein-Rathlou N-H, Robach P & Lundby C (2010). Recombinant human erythropoietin in humans down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate. J Physiol 589, 1273-1281.
36. Parisotto R, Gore C, Emslie K, Ashenden M, Brugnara C, Howe C, Martin D, Trout G & Hahn A (2000). A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 85, 564-572.
37. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving H-H, Remuzzi G, Singh AK, Solomon SD, Toto R & the TREAT Investigators (2009). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361, 2019-2032.
38. Phrommintikul A, Haas SJ, Elsik M & Krum H (2007). Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369, 381-388.
39. Pratt MC, Lewis-Barned NJ, Walker RJ, Bailey RR, Shand Bl & Livesey J (1992). Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34, 363-365.
40. Rasmussen P, Foged EM, Krogh-Madsen R, Nielsen J, Nielsen TR, Olsen NV, Petersen NC, Sorensen TA, Secher NH & Lundby C (2010). Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men. J Appl Physiol 109, 476-483.
41. Resch BE, Gaspar R, Sonkodi S & Falkay G (2003). Vasoactive effects of erythropoietin on human placental blood vessels in vitro. Am J Obstet Gynecol 188, 993-996.
42. Robach P, Cairo G, Gelfi C, Bernuzzi F, Pilegaard H, Vigano A, Santambrogio P, Cerretelli P, Calbet JAL, Moutereau S & Lundby C (2007). Strong iron demand during hypoxia-induced erythropoiesis is associated with down-regulation of iron-related proteins and myoglobin in human skeletal muscle. Blood 109, 4724-4731.
43. 2max depends on the severity of arterial hypoxemia. PLoS ONE 3, e2996.
44. Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ, Norgaard AM, Alberghini A, Campostrini N, Castagna A, Vigano A, Santambrogio P, Kempf T, Wollert KC, Moutereau S, Lundby C & Cairo G (2009). Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood 113, 6707-6715.
45. Rosenbaum M & Leibel RL (1999). The role of leptin in human physiology. N Engl J Med 341, 913-915.
46. Rundqvist H, Rullman E, Sundberg CJ, Fischer H, Eisleitner K, Stahlberg M, Sundblad P, Jansson E & Gustafsson T (2009). Activation of the erythropoietin receptor in human skeletal muscle. Eur J Endocrinol 161, 427-434.
47. Russell G, Gore C, Ashenden M, Parisotto R & Hahn A (2002). Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol 86, 442-449.
48. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M & Bode-Boger SM (2005). erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16, 892-898.
49. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, Busse L, Swift S, Elliott S & Begley CG (2010). Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115, 4264-4272.
50. Thomsen J, Rentsch R, Robach P, Calbet J, Boushel R, Rasmussen P, Juel C & Lundby C (2007). Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol 101, 481-486.
51. Wang XQ & Vaziri ND (1999). Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33, 894-899.
52. 2 uptake kinetics during exercise in humans. J Physiol 568, 639-652.